Authum Investment & Infrastructure bought 6.26 lakh shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
BSE-listed NBFC (market cap ~Rs 38,000 cr) controlled by Sanjay and Alpana Dangi, with around Rs 15,300 cr deployed across listed and unlisted Indian equities and credit. One of India's most aggressive listed proprietary investment vehicles, with concentrated multi-bagger positions and disclosed stakes in 10+ listed companies.
